Agilent Technologies, Inc. logo
Agilent Technologies, Inc. (A)
Compare

Agilent Technologies, Inc. (A) PEG Ratio: 9.41

Is Agilent Technologies, Inc.’s PEG ratio high or low?

Agilent Technologies, Inc.'s PEG ratio of 9.41 is 16% below its 5-year average of 11.21, near the low end of its 5-year range (0.56–34.23).

The PEG ratio for Agilent Technologies, Inc. (A) is 9.41. It is above its 12-month average by 25.22% (7.52).

A PEG Ratio Chart

A PEG Ratio
9.41+67.44% 1Y
Zoom

A Average PEG Ratio Chart

A Current vs Average PEG Ratio Chart

A PEG Ratio Metrics

PEG RATIO

9.41

PEG RATIO AVG TTM

7.52

PEG RATIO AVG 3Y

13.88

PEG RATIO AVG 5Y

11.21

PEG RATIO AVG 10Y

7.31

PEG RATIO AVG 15Y

5.93

PEG RATIO AVG 20Y

4.74

CURRENT VS TTM AVG

+25.22%

CURRENT VS 3Y AVG

-32.19%

CURRENT VS 5Y AVG

-16.09%

CURRENT VS 10Y AVG

+28.71%

CURRENT VS 15Y AVG

+58.79%

CURRENT VS 20Y AVG

+98.56%

A Competitors' PEG Ratio

NAMEMARKET CAPPEG RATIOTTM3Y5Y
Agilent Technologies, Inc. (A)9.417.5213.8811.21
Zoetis Inc. (ZTS)$34.20B2.042.963.833.78
Centene Corporation (CNC)$31.94BN/A0.180.160.16
IQVIA Holdings Inc. (IQV)$30.60B6.348.505.123.87
Humana Inc. (HUM)$43.78BN/A0.450.320.59
IDEXX Laboratories, Inc. (IDXX)$44.47B2.304.403.663.12
DexCom, Inc. (DXCM)$29.24B0.6619.9910.918.76
Biogen Inc. (BIIB)$29.00B0.340.340.240.23
Veeva Systems Inc. (VEEV)$27.37B1.421.475.645.88
Waters Corporation (WAT)$23.83B75.6275.6240.7827.51

Growth-Adjusted Valuation

PEG Ratio

9.41

P/E Ratio

26.4

Agilent Technologies, Inc. PEG Ratio Formula & Definition

PEG Ratio = PE Ratio / Earnings Growth Rate

The PEG ratio adjusts the PE ratio for expected earnings growth. A PEG near 1 is often considered fairly valued relative to growth.

Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute

Agilent Technologies, Inc. PEG Ratio FAQ

What is the PEG ratio for Agilent Technologies, Inc. (A)?
The PEG ratio for A stock is 9.41.
Is Agilent Technologies, Inc.'s PEG ratio high or low?
Agilent Technologies, Inc.'s PEG ratio of 9.41 is 16% below its 5-year average of 11.21, near the low end of its 5-year range (0.56–34.23).
What is the TTM average PEG ratio for Agilent Technologies, Inc. (A)?
The TTM average PEG ratio for A stock is 7.52.
What is the 3Y average PEG ratio for Agilent Technologies, Inc. (A)?
The 3Y average PEG ratio for A stock is 13.88.
What is the 5Y average PEG ratio for Agilent Technologies, Inc. (A)?
The 5Y average PEG ratio for A stock is 11.21.
What is the 10Y average PEG ratio for Agilent Technologies, Inc. (A)?
The 10Y average PEG ratio for A stock is 7.31.
What is the 15Y average PEG ratio for Agilent Technologies, Inc. (A)?
The 15Y average PEG ratio for A stock is 5.93.
What is the 20Y average PEG ratio for Agilent Technologies, Inc. (A)?
The 20Y average PEG ratio for A stock is 4.74.

Agilent Technologies, Inc. PEG Ratio History

DATEPEG RATIO
2025-10-319.41
2024-10-315.62
2023-10-3134.23
2022-10-316.25
2021-10-310.56
2019-10-310.09
2017-10-310.65
2016-10-311.68
2012-10-310.58
2011-10-310.19
2009-10-311.89
2008-10-310.46
2006-10-310.00
2002-10-310.01
2000-10-310.76
1999-10-310.16

About Agilent Technologies, Inc.

Agilent Technologies, Inc. delivers specialized, application-focused technologies and services to the global life sciences, diagnostics, and applied chemistry industries. Its Life Sciences and Applied Markets segment provides a comprehensive portfolio of analytical instrumentation. This includes liquid chromatography (LC) and gas chromatography (GC) systems, often integrated with mass spectrometry (MS) for advanced analysis (LC-MS, GC-MS). They also offer inductively coupled plasma mass spectrometry (ICP-MS), atomic absorption (AA), microwave plasma-atomic emission spectrometry (MP-AES), and inductively coupled plasma optical emission spectrometry (ICP-OES) instruments, alongside Raman spectroscopy for material characterization. Beyond spectroscopy, the segment supplies cell analysis solutions such as plate-based assays, flow cytometers, real-time cell analyzers, imaging systems, and microplate readers. Complementing these are various laboratory software, information management platforms, data analytics tools, automated and robotic lab systems, dissolution testing equipment, vacuum technology, and general measurement solutions. The Diagnostics and Genomics division offers cutting-edge tools for genetic and diagnostic research. These encompass arrays designed for DNA mutation detection, genotyping, gene copy number determination, identification of gene rearrangements, DNA methylation profiling, and gene expression analysis. This segment also provides target enrichment solutions for next-generation sequencing, along with software for genetic data management and interpretation. Furthermore, it synthesizes custom oligonucleotides. Other significant offerings include immunohistochemistry (IHC), in situ hybridization (ISH), hematoxylin and eosin (H&E) staining, and specialized staining solutions. The division also supplies consumables and software essential for quality control analysis of nucleic acid samples, as well as reagents for turbidimetry and flow cytometry applications. A key area of development for this segment is liquid-based pharmacodiagnostics. Agilent CrossLab, the third segment, focuses on providing essential laboratory consumables and services. Its product range features GC and LC columns, products for sample preparation, custom chemical formulations, and various supplies for laboratory instruments. Complementary services include expert support for startup, ongoing operations, training, compliance, Software-as-a-Service (SaaS) offerings, asset management, and professional consultation. The company's products reach customers through a diverse sales network, including direct sales teams, distributors, resellers, manufacturer's representatives, and its e-commerce platforms. Agilent Technologies, Inc. was established in 1999 and maintains its corporate headquarters in Santa Clara, California.

Santa Clara, CA
17,900 employees
Healthcare / Medical - Diagnostics & Research
Sector
Healthcare
Industry
Medical - Diagnostics & Research
CEO
Padraig McDonnell